Dr William Jenkins has been a Member of the Supervisory Board of Evotec AG from June 2006 to August 2008 and is a Member of the Scientific Advisory Board of Evotec AG since 2005. From 1999, he has been a Scientific Consultant to pharmaceutical companies and to investment companies in the life sciences sector. Prior to that, he was Head of Clinical Development & Regulatory Affairs for Novartis Pharma AG having held the same position pre-merger from 1992 with CIBA-Geigy AG. Previously, he was Head of Global Clinical Research at Glaxo from 1988.
Dr Jenkins is a Member of the Boards of Consort Medical plc (Hempel Hempstead, UK), BTG plc (London, UK), Eurand Pharmaceutical Holdings B.V. (Amsterdam, Netherlands) and Monogram Biosciences, Inc. (San Francisco, USA).
Dr Jenkins gained BA and MD degrees from the University of Cambridge and his earlier career was in medical research at the Royal Postgraduate Medical School and later as a Senior Lecturer at the Royal Free Hospital, London University.